— Fundamental Stock Analysis and Report Card
Located in San Diego, CA, US. DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Revenue, earnings and profitability.
Strong revenue growth and earnings can attract investors, driving the stock price up. Profitability indicates the company's efficiency and sustainability, which impacts investor confidence. Poor performance in these areas can lead to a decrease in stock price.
Revenue History
Earnings History
Margins
Income & Cash Flow analysis.
An income statement shows what a company earned and spent over a period — revenue at the top, costs and expenses in between, and net income at the bottom. A cash flow statement tracks the actual cash moving in and out, across operations, investing, and financing. Read together, they show whether reported earnings are backed by real cash.
Q1 2026 Total ($) | Q1 2026 Margin (%) | |
|---|---|---|
| Revenue | 1.2b +155.9m +15.0% | |
| Gross Income | 750.3m +161.3m +27.4% | 63% +6.1pp +10.7% |
| EBITDA | 336.6m +117.6m +53.7% | 28% +7.1pp +33.6% |
| Operating Income | 255.3m +121.6m +90.9% | 21% +8.5pp +66.0% |
| Net Income | 199.5m +94.1m +89.3% | 17% +6.6pp +64.5% |
| Earnings Per Share | 0.52 +0.3 +92.6% | |
| Operating Cash Flow | 525.6m +341.8m +186.0% | 44% +26.4pp +148.6% |
| Free Cash Flow | 449.0m +352.2m +363.8% | 38% +28.3pp +303.2% |
| Research & Development | 145.3m +100.0k +0.1% | 12% -1.8pp -13.0% |